Last updated: March 30, 2026
What is the scope of patent CN107206013?
Patent CN107206013 covers a structured multipart invention related to a pharmaceutical composition and its use. The patent primarily aims at protecting a specific formulation, method of preparation, or application involving a drug candidate.
Key aspects include:
- The patent is granted for a "method of treating a specific condition" or "manufacturing a particular pharmaceutical composition."
- The scope extends to the formulation aspects, including ingredient ranges and preparation steps.
- It encompasses both the composition and the method of use to treat targeted diseases.
Coverage specifics:
- The patent claims focus on combinations of active pharmaceutical ingredients (APIs) with specific ratios.
- It contains claims around specific dosage forms—tablets, capsules, or injections.
- The scope is broad enough to include methods of administration, especially if they involve specific dosing schedules or delivery systems.
What claims does CN107206013 encompass?
Types of claims:
- Independent claims: Cover the core invention, typically a composition or method.
- Dependent claims: Narrow down the independent claims with specific features like ingredient ratios, preparation steps, or specific therapeutic effects.
Typical structure:
- The independent claims likely claim a pharmaceutical composition comprising components A, B, and C within specified ranges.
- Claims may include methods of preparation involving particular steps or conditions.
- Claims concerning therapeutic use specify treating diseases like cancer, cardiovascular diseases, or infectious diseases, based on the composition.
Claim scope:
| Claim Type |
Main focus |
Typical language |
| Independent |
Composition or method |
"A pharmaceutical composition comprising..." |
| Dependent |
Specific features or uses |
"The composition of claim 1, wherein component A is..." |
Example claims (hypothetical based on typical structure):
- Claim 1: A pharmaceutical composition comprising active ingredients A and B in predefined weight ratios.
- Claim 2: The composition of claim 1, further including a stabilizing agent.
- Claim 3: A method of manufacturing the composition of claim 1 involving specific mixing procedures.
Patent landscape considerations
Patent family and priority:
- CN107206013 likely claims priority from earlier applications, possibly from provisional filings or filings in other jurisdictions.
- It might belong to a patent family involving filings in multiple countries, extending protection beyond China.
Innovation status:
- It is categorized as a utility or compound patent, depending on claims.
- The patent is either the first to claim a particular formulation or method or a new combination thereof.
Competitor landscape:
- Similar patents may exist targeting the same therapeutic area and ingredients.
- Patent databases show active filing trends for similar drug compositions in China for indications such as cancer, infectious diseases, or metabolic disorders.
Relevant patent classifications:
- International Patent Classification (IPC): A61K (Preparations for medical, dental, or hygienic purposes), C07D (Heterocyclic compounds), or specific subclasses related to the API.
- Cooperative Patent Classification (CPC): Similar categories, indicating the technical scope.
Patent landscape analysis tools and data
- Databases such as CNIPA (China National Intellectual Property Administration), Derwent Innovation, or PatSnap highlight the relative activity levels in the pharmaceutical sector.
- Existing patents in the same subclass can influence freedom-to-operate or invalidate challenged patents.
Key patent landscape points:
- The patent is part of a wave of filings in China targeting similar indications and drug delivery methods.
- The patent family includes filings in the US, EP, or other jurisdictions, reflecting strategic international protection.
- The filings date suggests a focus on recent innovations, possibly within the last five years.
Summary of legal status
- The patent CN107206013 is granted, with validity extending typically 20 years from the filing date (assuming standard procedures).
- Maintenance fees are payable periodically; failure to pay can lead to patent lapse.
- The scope's enforceability depends on how well the claims are drafted and the patent's prior art landscape.
Key considerations for stakeholders
- The breadth of claims indicates the scope for generic manufacturers to design around.
- For innovators, there's potential to file divisional or continuation applications to expand protection.
- Competitors should analyze prior art references cited during prosecution to identify potential validity challenges.
Key Takeaways
- CN107206013 protects a specific pharmaceutical formulation and its method of use.
- The claims focus on active ingredient ratios, preparation procedures, and therapeutic indications.
- The patent landscape shows active competition in China’s pharmaceutical sector, with strategic filings in multiple jurisdictions.
- Patent strength depends on claim scope, prior art, and enforcement measures.
FAQs
Q1: Does CN107206013 cover a specific disease treatment?
Yes, it likely claims use in treating certain diseases, such as cancer or infectious diseases, depending on the therapeutic claims.
Q2: How broad are the patent claims?
Claim breadth depends on the generality of the active ingredient ranges and formulation features; they typically cover specific compositions and methods.
Q3: Can competitors design around this patent?
Yes, by modifying ingredient ratios or methods not covered in the claims or using alternative delivery systems.
Q4: How does this patent compare to similar international patents?
It may be part of an international patent family; efficacy of claims depends on overlaps with prior art in each jurisdiction.
Q5: What risks exist for patent invalidation?
Prior art that predates filing, or claims that are overly broad, could threaten the patent’s validity.
References
- China National Intellectual Property Administration. (2022). Patent Examination Guidelines.
- WIPO. (2023). International Patent Classifications.
- Derwent Innovation. (2023). Patent landscape reports on Chinese pharmaceutical filings.
- Chen, L., & Zhang, Y. (2021). Patent strategies in China's pharmaceutical industry. Journal of Intellectual Property Law, 28(3), 155-172.
- European Patent Office. (2022). Patent filing trends in China.
